Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFB | P00751 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034824 | 0.89 | DRD2 (0.47) | CFBGBA1SIGMAR1 | |
| SCHEMBL6497571 | 0.89 | CFB (0.47) | CFBGBA1SIGMAR1ALDH1A1MAPT | |
| SCHEMBL6042431 | 0.88 | CFB (0.47) | CFBGBA1SIGMAR1ALDH1A1MAPT | |
| SCHEMBL3901486 | 0.85 | NPC1 (0.45) | CFBGBA1NPC1RAB9A | |
| SCHEMBL3893163 | 0.81 | GBA1 (0.43) | CFBGBA1SIGMAR1NPC1RAB9A | |
| SCHEMBL21625238 | 0.80 | MEN1 (0.50) | CFBALDH1A1MAPT | |
| SCHEMBL30768210 | 0.80 | MEN1 (0.50) | CFBALDH1A1MAPT | |
| SCHEMBL3892581 | 0.80 | KDM4E (0.46) | CFBSIGMAR1ALDH1A1NPC1RAB9A | |
| SCHEMBL3890373 | 0.79 | DRD2 (0.42) | CFB | |
| SCHEMBL9070276 | 0.78 | DRD2 (0.53) | CFBALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498344-B2 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| EP-0867183-B1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. | 2004-09-23 | — | — | US | disclosed |
| US-6706734-B2 | ANTIISCHEMIC AGENTS; ANTICONVULSANTS; HEADACHES | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-0867183-A1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1998-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | CFB 2874/4885GBA1 967/4885SIGMAR1 1167/4885 |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | CFB 2874/4885GBA1 967/4885SIGMAR1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.